Review ArticleMethylphenidate for the Treatment of Parkinson Disease and Other Neurological DisordersAuriel, Eitan MD*; Hausdorff, Jeffrey M. PhD*†‡; Giladi, Nir MD*†Author Information *Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center; †Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; and ‡Division of Aging, Harvard Medical School, Boston, MA. Address correspondence and reprint requests to Nir Giladi, MD, Department of Neurology, Tel Aviv Sourasky Medical Center, 6 Weitzman St, Tel Aviv, Israel; E-mail: email@example.com Supported by grants from the National Parkinson Foundation, Miami, FL, and from the National Institutes of Health. Clinical Neuropharmacology: March-April 2009 - Volume 32 - Issue 2 - p 75-81 doi: 10.1097/WNF.0b013e318170576c Buy Metrics Abstract Methylphenidate (MPH) is a central nervous system stimulant derived from an amphetamine and acts as a potent inhibitor of catecholamine reuptake and increases dopamine levels in the brain. Methylphenidate is widely used for the treatment of children and adults with attention deficit hyperactivity disorder. Because the dopaminergic system is critical to the pathological process in Parkinson disease (PD), it has been suggested that MPH, which increases dopaminergic stimulation at the postsynaptic receptor level, may provide symptomatic relief in PD patients. This article reviews those studies that have evaluated the potential of MPH to treat the motor and cognitive aspects of PD, summarizes the evidence for clinical use in other neurological diseases, and briefly reviews the physiological mechanisms whereby MPH may bring about its therapeutic effects. Methylphenidate does seem to be useful for ameliorating cognitive, affective, and motor deficits in PD and in other neurological patients; however, additional studies are needed before MPH can be routinely prescribed as an adjunct therapy in these populations. © 2009 Lippincott Williams & Wilkins, Inc.